Search Results - "Tigges, Ann M."

Evolution of Treatment-Emergent Resistant Variants in Telaprevir Phase 3 Clinical Trials by Sullivan, James C., De Meyer, Sandra, Bartels, Doug J., Dierynck, Inge, Zhang, Eileen Z., Spanks, Joan, Tigges, Ann M., Ghys, Anne, Dorrian, Jennifer, Adda, Nathalie, Martin, Emily C., Beumont, Maria, Jacobson, Ira M., Sherman, Kenneth E., Zeuzem, Stefan, Picchio, Gaston, Kieffer, Tara L.

“…Background. Telaprevir (TVR), a hepatitis C virus (HCV) NS3/4A protease inhibitor, has been approved to treat genotype 1 HCV. To understand the clinical impact…”
Get full text

Hepatitis C Virus Variants with Decreased Sensitivity to Direct-Acting Antivirals (DAAs) Were Rarely Observed in DAA-Naive Patients prior to Treatment by Bartels, Doug J, Sullivan, James C, Zhang, Eileen Z, Tigges, Ann M, Dorrian, Jennifer L, De Meyer, Sandra, Takemoto, Darin, Dondero, Elizabeth, Kwong, Ann D, Picchio, Gaston, Kieffer, Tara L

“…Article Usage Stats Services JVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Natural Prevalence of Hepatitis C Virus Variants with Decreased Sensitivity to NS3·4A Protease Inhibitors in Treatment-Naive Subjects by Bartels, Doug J., Zhou, Yi, Zhang, Eileen Z., Marcial, Michelle, Byrn, Randal A., Pfeiffer, Thomas, Tigges, Ann M., Adiwijaya, Bambang S., Lin, Chao, Kwong, Ann D., Kieffer, Tara L.

“…Background. The prevalence and clinical implications of naturally occurring variants that are resistant to hepatitis C virus (HCV) protease inhibitors in…”
Get full text

Modeling viral evolutionary dynamics after telaprevir-based treatment by Haseltine, Eric L, De Meyer, Sandra, Dierynck, Inge, Bartels, Doug J, Ghys, Anne, Davis, Andrew, Zhang, Eileen Z, Tigges, Ann M, Spanks, Joan, Picchio, Gaston, Kieffer, Tara L, Sullivan, James C

“…For patients infected with hepatitis C virus (HCV), the combination of the direct-acting antiviral agent telaprevir, pegylated-interferon alfa (Peg-IFN), and…”
Get full text

Phenotypic Characterization of Resistant Val36 Variants of Hepatitis C Virus NS3-4A Serine Protease by Zhou, Yi, Bartels, Doug J, Hanzelka, Brian L, Müh, Ute, Wei, Yunyi, Chu, Hui-May, Tigges, Ann M, Brennan, Debra L, Rao, B Govinda, Swenson, Lora, Kwong, Ann D, Lin, Chao

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Natural Prevalence of Hepatitis C Virus Variants with Decreased Sensitivity to NS3.4A Protease Inhibitors in Treatment-Naive Subjects by Bartels, Doug J., Zhou, Yi, Zhang, Eileen Z., Marcial, Michelle, Byrn, Randal A., Pfeiffer, Thomas, Tigges, Ann M., Adiwijaya, Bambang S., Lin, Chao, Kwong, Ann D., Kieffer, Tara L.

“…Background. The prevalence and clinical implications of naturally occurring variants that are resistant to hepatitis C virus (HCV) protease inhibitors in…”
Get full text

Phenotypic and Structural Analyses of Hepatitis C Virus NS3 Protease Arg155 Variants by Zhou, Yi, Muöh, Ute, Hanzelka, Brian L., Bartels, Doug J., Wei, Yunyi, Rao, B. Govinda, Brennan, Debra L., Tigges, Ann M., Swenson, Lora, Kwong, Ann D., Lin, Chao

“…Telaprevir (VX-950) is a highly selective, potent inhibitor of the hepatitis C virus (HCV) NS3·4A serine protease. It has demonstrated strong antiviral…”
Get full text

Modeling Viral Evolutionary Dynamics after Telaprevir-Based Treatment: e1003772 by Haseltine, Eric L, Meyer, Sandra De, Dierynck, Inge, Bartels, Doug J, Ghys, Anne, Davis, Andrew, Zhang, Eileen Z, Tigges, Ann M, Spanks, Joan, Picchio, Gaston, Kieffer, Tara L, Sullivan, James C

“…For patients infected with hepatitis C virus (HCV), the combination of the direct-acting antiviral agent telaprevir, pegylated-interferon alfa (Peg-IFN), and…”
Get full text

Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon alpha by Zhou, Yi, Müh, Ute, Hanzelka, Brian L, Bartels, Doug J, Wei, Yunyi, Rao, B Govinda, Brennan, Debra L, Tigges, Ann M, Swenson, Lora, Kwong, Ann D, Lin, Chao

“…Telaprevir (VX-950) is a highly selective, potent inhibitor of the hepatitis C virus (HCV) NS3.4A serine protease. It has demonstrated strong antiviral…”
Get full text

Phenotypic and Structural Analyses of Hepatitis C Virus NS3 Protease Arg super(155) Variants: Sensitivity To Telaprevir (VX-950) And Interferon alpha by Zhou, Yi, Mueh, Ute, Hanzelka, Brian L, Bartels, Doug J, Wei, Yunyi, Rao, BGovinda, Brennan, Debra L, Tigges, Ann M, Swenson, Lora, Kwong, Ann D, Lin, Chao

“…Telaprevir (VX-950) is a highly selective, potent inhibitor of the hepatitis C virus (HCV) NS3.4A serine protease. It has demonstrated strong antiviral…”
Get full text

Phenotypic Characterization of Resistant Val super(36) Variants of Hepatitis C Virus NS3-4A Serine Protease by Zhou, Yi, Bartels, Doug J, Hanzelka, Brian L, Mueh, Ute, Wei, Yunyi, Chu, Hui-May, Tigges, Ann M, Brennan, Debra L, Rao, BGovinda, Swenson, Lora, Kwong, Ann D, Lin, Chao

“…In patients chronically infected with hepatitis C virus (HCV) strains of genotype 1, rapid and dramatic antiviral activity has been observed with telaprevir…”
Get full text

Phenotypic Characterization of Resistant Val 36 Variants of Hepatitis C Virus NS3-4A Serine Protease by Zhou, Yi, Bartels, Doug J., Hanzelka, Brian L., Müh, Ute, Wei, Yunyi, Chu, Hui-May, Tigges, Ann M., Brennan, Debra L., Rao, B. Govinda, Swenson, Lora, Kwong, Ann D., Lin, Chao

“…ABSTRACT In patients chronically infected with hepatitis C virus (HCV) strains of genotype 1, rapid and dramatic antiviral activity has been observed with…”
Get full text